There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aimmune Therapeutics (NASDAQ: AIMT), Clearside Biomedical (NASDAQ: CLSD) and ImmunoGen (NASDAQ: IMGN) with bullish sentiments.
Aimmune Therapeutics (NASDAQ: AIMT)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aimmune Therapeutics (NASDAQ: AIMT), with a price target of $72. The company’s shares opened today at $32.69.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.0% and a 44.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Aimmune Therapeutics is Strong Buy and the average price target is $64.60, representing a 97.6% upside.
In a report issued on May 18, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Clearside Biomedical (NASDAQ: CLSD)
Cowen & Co. analyst Boris Peaker assigned a Buy rating to Clearside Biomedical (NASDAQ: CLSD) today. The company’s shares opened today at $14.54, close to its 52-week high of $15.33.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 19.1% and a 54.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $22.80.
ImmunoGen (NASDAQ: IMGN)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on ImmunoGen (NASDAQ: IMGN), with a price target of $20. The company’s shares opened today at $10.47.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 18.8% and a 47.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Aileron Therapeutics Inc.
Currently, the analyst consensus on ImmunoGen is Moderate Buy and the average price target is $14.80, representing a 41.4% upside.
In a report issued on May 17, H.C. Wainwright also assigned a Buy rating to the stock with a $18 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
